Navigation Links
AVANIR Pharmaceuticals To participate in two conferences in March
Date:3/1/2013

ALISO VIEJO, Calif., March 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

  • Cowen & Company 33rd Annual Healthcare Conference
    • Location: Boston Marriott Copley Place, Boston, MA
    • Presentation date: Tuesday March 5, 2013
    • Presentation time: 9:20 a.m. E.T.
  • 25th Annual ROTH Conference
    • Location: Ritz-Carlton, Laguna Niguel, CA
    • Presentation date: Wednesday March 20, 2013
    • Presentation time: 11:30 a.m. P.T.

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements , PhD
ir@avanir.com
+1 (949) 389-6700


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
2. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Ecovia ... Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). Under the ... to develop a suite of BioGel™ biopolymer materials for hygiene applications, particularly for ...
(Date:3/28/2017)... -- The National Pharmaceutical Council (NPC) today announced that Ipsen ... as its newest member. David Cox , PhD, ... America ), will serve as his company,s representative ... to have Ipsen and Dr. Cox join NPC as ... welcome their insights in helping us identify and address ...
(Date:3/28/2017)... ... 2017 , ... Currently symptomatic therapies for Parkinson’s Disease (PD) ... in STEM CELLS suggests that human neural stem cell (hNSC) transplantation could help ... neural cells. , Strategies involving transplantation of these cells into the affected ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search ... with Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a ... is a leader in a wide range of services related to laboratory testing ...
Breaking Biology Technology:
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
Breaking Biology News(10 mins):